secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2025-07-28T23:59:59+00:00
Accession:  0001178913-25-002484
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio wins FDA agreement to use BMD as primary endpoint for EB613 Phase 3 osteoporosis study
--------------------------------------------------------------------------------

- FDA agreed single 24-month, placebo-controlled Phase 3 study with total hip BMD as primary endpoint; fracture incidence as key secondary.
- Shift from traditional fracture-endpoint trials; no dedicated oral carcinogenicity or DART studies required by FDA.
- Phase 3 study targets postmenopausal women; EB613 is first oral anabolic tablet for osteoporosis.
- FDA's SABRE qualification still expected later this year but not needed to proceed.
- CEO Miranda Toledano calls it a major milestone; no new osteoporosis drug approved by FDA since 2019.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891325002484/0001178913-25-002484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891325002484/zk2533483.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-002484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer